August 17, 2011

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program for Mycobacterium tuberculosis and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST)

Subject: Preliminary Report for Panel Shipment May 9, 2011

Dear Participant:

Attached you will find the preliminary susceptibility testing results for the cultures of M. tuberculosis sent to your laboratory in May 2011. (You may also access the report at http://wwwn.cdc.gov/mpep/mtbds.aspx) These preliminary results were determined by the candidate reference laboratories and may not represent the consensus of all participants. Although the CDC recommends the broth-based methods for routine M. tuberculosis drug susceptibility testing, this preliminary report provides the results obtained by using the reference agar proportion method, except in the case of pyrazinamide, where BACTEC MGIT 960 is the reference method. Participants should use the equivalent critical concentrations for testing methods, as defined in CLSI M-24A standards, to determine their results.

This preliminary report will provide you with timely information about the cultures sent to your laboratory. Subsequently, a detailed aggregate report of susceptibility testing results and methods reported by all participants for this panel of five (5) M. tuberculosis complex isolates will be emailed.

For additional information or to comment on this report, you may call Suzette Brown at 1-888-465-6062 or 404 498-2283 or email mtbntmdst@cdc.gov or snp4@cdc.gov. You may also contact Beverly Metchock at 404 639-1285 or email BMetchock@cdc.gov.

We appreciate your continued interest and participation in the CDC Model Performance Evaluation Program for Mycobacterium tuberculosis and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST).

Sincerely yours,

Suzette A. Brown, MS
Project Coordinator
Model Performance Evaluation Program
NCEZID/DPEI/LSDB
Centers for Disease Control and Prevention
Ph : 404 718-4603
e-mail : snp4@cdc.gov
**Preliminary Report**

Susceptibility Testing Results:
*M. tuberculosis Isolates*
Panel Shipment May 9, 2011

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Susceptibility Testing Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Resistant to Ofloxacin (OFL) @ 2µg/ml</td>
</tr>
<tr>
<td>B</td>
<td>Resistant to Isoniazid (INH) @ 0.2µg/ml</td>
</tr>
<tr>
<td>C</td>
<td>Susceptible to all first-and second-line drugs</td>
</tr>
</tbody>
</table>
| D       | Resistant to Isoniazid (INH) @ 0.2µg/ml and 1µg/ml  
Resistant to Streptomycin (SM) @ 2µg/ml and 10µg/ml |
| E       | Resistant to Rifampin (RIF) @ 1µg/ml |